총 28건

해외임상승인현황 정보 :: 순번, 임상시험 제목, 적응증, 연구설계, 의뢰자/실시기관, 임상단계, 게시일자
순번 임상시험 제목 적응증 연구설계 의뢰자/실시기관 임상단계 게시일자
1 An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma Gastric Cancer|Cancer of the Stomach|Stomach Cancer|Gastroesophageal Junction Biological: Relatlimab + Nivolumab|Biological: Nivolumab|Drug: Paclitaxel|Drug: Ramucirumab Bristol-Myers Squibb Phase 2 2019-05-17
2 A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer Urinary Bladder Neoplasm|Neoplasm Metastasis Biological: Bempegaldesleukin|Biological: Nivolumab Nektar Therapeutics|Bristol-Myers Squibb Phase 2 2019-04-29
3 A Study Comparing Risankizumab to Placebo in Subjects With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy Psoriatic Arthritis Biological: placebo for rizankizumab|Biological: risankizumab AbbVie Phase 3 2019-03-25
4 A Study Comparing Risankizumab to Placebo in Subjects With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) Psoriatic Arthritis Biological: placebo for rizankizumab|Biological: risankizumab AbbVie Phase 3 2019-03-07
5 A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients With Manifest Huntington's Disease Huntingtons Disease Drug: RO7234292|Drug: Placebo Hoffmann-La Roche Phase 3 2019-01-23
6 Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents With Severe, Uncontrolled Asthma Asthma Biological: Tezepelumab|Other: Placebo AstraZeneca|Amgen Phase 3 2019-01-07
7 Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS Relapsing Multiple Sclerosis Biological: Ofatumumab|Biological: Tetanus toxoid (TT) containing vaccine (Td, Tdap)|Biological: 13-valent pneumococcal conjugate vaccine (13-PCV)|Biological: 23-valent pneumococcal polysaccharide vaccine (23-PPV)|Biological: Seasonal Quadrivalent influenza vaccine|Biological: Keyhole limpet hemocyanin (KLH) neo-antigen Novartis Pharmaceuticals|Novartis Phase 3 2018-12-28
8 A Study of NKTR-214 in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC) Renal Cell Carcinoma|Metastatic Renal Cell Carcinoma Biological: Bempegaldesleukin|Drug: Sunitinib|Biological: Nivolumab|Drug: Cabozantinib Nektar Therapeutics|Bristol-Myers Squibb Phase 3 2018-12-18
9 Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689) Head and Neck Neoplasms Biological: Pembrolizumab 200 mg|Radiation: Radiotherapy 60 Gray/day|Radiation: Radiotherapy 66 Gray/day|Radiation: Radiotherapy 70 Gray/day|Drug: Cisplatin 100 mg/m^2 Merck Sharp & Dohme Corp. Phase 3 2018-12-17
10 PROPEL Study - A Study Comparing ATB200/AT2221 With Alglucosidase/Placebo in Adult Subjects With LOPD Pompe Disease (Late-onset) Drug: AT2221|Biological: alglucosidase alfa|Biological: ATB200 Amicus Therapeutics Phase 3 2018-12-04